tbuckley/cabot-search huggingface dataset:
Bendamustine and Rituximab Versus Dexamethasone, Rituximab and Cyclophosphamide in Patients with Waldenstrom Macroglobulinemia (WM)
Authors: Jonas Paludo, Jithma P Abeykoon, Amber B Hesse, Amanda Shreders, Sikander Ailawadhi, Stephen Ansell, Morie A. Gertz, Craig B. Reeder, Rebecca L King, Robert A. Kyle, Francis K Buadi, Angela Dispenzieri, Martha Q. Lacy, Thomas M. Habermann, David Dingli, Thomas E. Witzig, Ronald S. Go, Wilson I Gonsalves, Nelson Leung, Yi Lin, John A Lust, S. Vincent Rajkumar, Shaji Kumar, Prashant Kapoor
Journal: Blood (2016)
Abstract P5-03-11: Germline and somatic variants in patients with inflammatory breast cancer (IBC) detected using cell-free DNA
Authors: Jennifer S. Winn, Zachary Hasse, Jianming Pei, Michael Slifker, Sebastian M. Arisi-Fernandez, Jacqueline N. Talarchek, Elias Obeid, Karthik Devarajan, Hong Wu, Yulan Gong, Massimo Cristofanilli, R.Katherine Alpaugh, Sandra Viviana Fernandez
Journal: Cancer Research (2020)

Abstract In order to better understand the etiology of inflammatory breast cancer (IBC), we performed a retrospective study to evaluate genomic alterations in 32 IBC patients using circulating DNA from blood. In 20 patients, mutation analyses were also conducted on tumor tissue or tumor cells from pleural effusions; in 15 of these patients, blood and tissue or pleural effusions were collected at the same time. Next generation sequencing (NGS) and a panel of 93 breast cancer related genes (Qiagen) were used for these studies. We found that of the 32 total patients, 11 (34.4%) carried at least one putative pathogenic germline variant, and another 8 patients (25%) carried at least one likely pathogenic germline variant. Ten patients (31.3%) carried only germline variants of uncertain significance and in 3 patients (9.4%) germline variants were not detected. Putative germline pathogenic variants were observed in the BRCA2 (2/32), TP53 (2/32), BRCA1 (1/32), PALB2 (1/32), CHEK2 (1/32), ATM (1/32), PMS1 (1/32), MUTYH (1/32), and MSH2 (1/32) genes. In addition, putative germline likely pathogenic variants were observed in the BARD1 (10/32), RB1 (2/32), APC (1/32), FANCC (1/32), AR (1/32), RAD51C (1/32), RAD51D (1/32) and CASP8 (1/32) genes. Most of the patients in our study had a family history of cancer and seventeen of the patients (53.1%) had family history of breast cancer in particular. Of those patients, 7 had a family history of breast cancer at a young age (&amp;lt;45 years old). Other cancer in their families included prostate (28.1%), colon (28.1%) and skin cancer (12.5%). Somatic variants, pathogenic or likely pathogenic, were detected in: TP53, PTEN, MRE11, PMS2, RB1, AR, KMT2C, PIK3CA and BRCA1. These results suggest a high incidence of germline variants in patients with IBC that could be associated with an increased risk of developing the disease. This data, if validated in a larger cohort, would demonstrate the power that genomic analysis has to identify women at high-risk of developing IBC and who would benefit from early screening. Citation Format: Jennifer S. Winn, Zachary Hasse, Jianming Pei, Michael Slifker, Sebastian M. Arisi-Fernandez, Jacqueline N. Talarchek, Elias Obeid, Karthik Devarajan, Hong Wu, Yulan Gong, Massimo Cristofanilli, R.Katherine Alpaugh, Sandra Viviana Fernandez. Germline and somatic variants in patients with inflammatory breast cancer (IBC) detected using cell-free DNA [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P5-03-11.
Abstract MP68: The Association Of Long-term Air Pollution Exposure With Left Ventricular Structure And Function In The Multi-ethnic Study Of Atherosclerosis
Authors: Thomas R Austin, Colleen Sitlani, Sara Lindström, Bruce M Psaty, Joao Lima, Joel D Kaufman, Susan R Heckbert
Journal: Circulation (2021)

Background: Air pollution contributes to cardiovascular morbidity, including heart failure. Exposure to pollutants has been associated with hypertension and inflammation, which contribute to cardiac remodeling. Few studies have investigated long-term air pollution concentrations and measures of cardiac structure, and no large longitudinal analyses have investigated this association. Hypothesis: Long-term air pollution concentrations are associated with magnetic resonance imaging-derived measures of left ventricular structure and function. Methods: In the Multi-Ethnic Study of Atherosclerosis (MESA), we investigated cross-sectional and longitudinal associations between modeled fine particulate matter (PM2.5), oxides of nitrogen (NOX) and ozone (O3) concentrations and left ventricular mass index (LVMI), mass to volume ratio, ejection fraction, and circumferential strain by cardiac magnetic resonance imaging (CMR) at two time points roughly 10 years apart. Multivariable linear regression was used to estimate the association between pollutants and both cross-sectional and longitudinal CMR measures. Results: At MESA Exam 1 (2000-2002), 4,825 participants in our cross-sectional analysis sample had a mean age of 61 years (standard deviation: 10), 53% were women, 40% were white, 13% were Chinese-American, 25% were African-American, and 21% were Hispanic. At Exam 1, Higher concentrations of PM2.5 and NOX in the year prior to Exam 1 were associated with higher LVMI at Exam 1 (1.6% per 5ug/m3 higher PM2.5, 95% CI: 0.3, 2.9; 1.8% per 40 parts per billion [ppb] NOX, 95% CI: 0.3, 3.3) and higher O3 was associated with lower LVMI (-3.5% per 10ppb, 95% CI: -6.0, -1.0). In longitudinal analyses, higher NOX was associated with a worsening of LV circumferential strain (-0.87% per 40ppb, 95% CI: -1.69, -0.05). Conclusions: Our study offers mixed evidence of a cross-sectional association between higher PM2.5 and NOx concentrations and greater LVMI. We also found associations between greater O3 concentration and lower cross-sectional LVMI, though this association may be confounded by other pollutants. These findings suggest a role for NOX, PM2.5, and O3 in cardiac remodeling. Additional work is needed to clarify that role and better understand the biological underpinnings of these associations.
Evaluation of <i>POLE</i>/<i>POLD1</i> Variants as Potential Biomarkers for Immune Checkpoint Inhibitor Treatment Outcomes—Reply
Authors: Feng Wang, Qi Zhao, Rui-Hua Xu
Journal: JAMA Oncology (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Abstract MP57: Lactation Duration is Associated With Lower Visceral and Pericardial Fat Volumes in Parous Women: 25-year Follow-up in the Cardia Study
Authors: Duke Appiah, Cora E Lewis, Jeff Carr, Myron D Gross, David R Jacobs, Stephen Sidney, James M Shikany, Charles P Quesenberry, Erica P Gunderson
Journal: Circulation (2020)

Introduction: Lactation has been associated with a lower risk of incident type 2 diabetes mellitus and cardiovascular disease (CVD) in women. However, the underlying mechanisms for these associations are not well understood. The longitudinal association between lactation and maternal fat volume has rarely been investigated. Hypothesis: We tested the hypothesis that lactation duration is inversely associated with maternal visceral and pericardial fat volumes. Methods: Data were obtained from 910 women enrolled in the Coronary Artery Risk Development in Young Adults (CARDIA) study (1985-86) without diabetes prior to pregnancy who had ≥1 birth during 25 years of follow-up. Cumulative lactation duration across all births since baseline was calculated from self-reports collected at each exam. Volumes of visceral and pericardial adipose tissue were measured from computed tomographic scans at the Year 25 exam in 2010-2011. Methods: At baseline, the average age of women (48% black, 52% white) was 24 years (range: 18-30 years). During 25 years of follow-up, 76% of women reported lactation duration of ≥ 1 month. In adjusted linear regression models, lactation duration was inversely associated with visceral fat (p=0.021) and pericardial fat (p=0.001) volumes (Table). There was a significant interaction between race and lactation on visceral (p=0.035) and pericardial fat (p=0.027) volumes (Table). Formal mediation analysis showed a significant indirect effect of lactation duration on visceral (p=0.001) and pericardial fat (p=0.002) volumes through body weight change between the first postbaseline birth and the end of follow-up. Changes in body weight mediated 29.4% and 26.0% of the association between lactation duration and visceral and pericardial fat volumes. Conclusions: In this prospective study, the associations of longer lactation duration with lower visceral and pericardial fat volumes were partially mediated by body weight changes.
Chinese doctors admitted in undercover calls that harvested organs were available, informal tribunal finds
Authors: Gareth Iacobucci
Journal: BMJ (2020)

Doctors from leading Chinese hospitals admitted in undercover phone calls that organs harvested from Falun Gong detainees were available, an informal, independent “people’s tribunal” has disclosed.

The seven member panel concluded last year1 that mass forced organ harvesting from prisoners of conscience in China over years constitutes crimes against humanity under international law.

The tribunal has now released a more detailed body of evidence that it says supports its conclusion that China is guilty of a continuing, state run programme of forced organ harvesting from innocent prisoners of conscience.

Geoffrey Nice QC, the leading war crimes prosecutor who chaired the panel, said, “It is now the responsibility of all those who interact with …
A multivariate prognostic nomogram incorporating PSA kinetics in hormone-refractory metastatic prostate cancer (HRPC)
Authors: M. Eisenberger, E. S. Garrett-Mayer, Y. Ou Yang, R. de Wit, I. Tannock, A. J. Armstrong
Journal: Journal of Clinical Oncology (2007)

5058 Background: To develop a prognostic model and nomogram using baseline clinical variables to predict death among men with metastatic hormone-refractory prostate cancer (HRPC). Methods: TAX 327 was a clinical trial that randomized 1,006 men with metastatic HRPC to receive 3-weekly or weekly docetaxel or mitoxantrone, each with prednisone. Of these, 635 men had baseline data that included PSA kinetics, with 518 mortality events recorded as of November 2006. We developed a multivariate Cox model and nomogram to predict survival at two, three, and five years. Results: Ten independent prognostic factors were identified in multivariate analysis and include: 1) presence of liver metastases (HR 1.64, p=0.02), 2) number of metastatic sites (HR 1.58 if =2 sites, p=0.001), 3) clinically significant pain at baseline (HR 1.46, p&lt;0.0001), 4) Karnofsky Performance Status (HR 1.42 if =70, p=0.01), 5) type of progression at baseline (HR 1.40 for measurable disease progression and 1.28 for bone scan progression, p=0.002 and 0.014 respectively), 6) pretreatment PSA doubling time (PSADT, HR 1.20 if &lt;55 days, p=0.048), 7) baseline PSA (HR 1.17 per log rise, p&lt;0.0001), 8) tumor grade (HR 1.18 for high grade, p=0.076), 9) alkaline phosphatase (HR 1.26 per log rise, p&lt;0.0001), and 10) hemoglobin (HR 1.10 per unit decline, p=0.006). A PSADT &lt;55 days (median value for this dataset) was associated with other adverse prognostic factors, but was independently associated with shortened overall survival. Men with a PSA less than the median of 114 ng/ml and longer PSADT (=55 days) had a median survival of 24.7 months, while those with higher PSA and shorter PSADT had a median survival of 13.8 months. A nomogram was developed based on this Cox multivariate model and validated internally using bootstrap methods, with a concordance index of 0.69. Conclusions: This multivariate model identified several prognostic factors in men with metastatic HRPC including PSADT, and led to the successful development of a clinically applicable nomogram. External prospective validation may support the wider use of this prognostic baseline model for men with HRPC treated with chemotherapy. No significant financial relationships to disclose.
Abstract P274: Kidney Filtration Markers and the Risk of Clinical Outcomes in Individuals With Type 2 Diabetes in the Advance Trial
Authors: Hyunju Kim, Dan Wang, John Chalmers, Mark Woodward, Elizabeth Selvin, Casey M Rebholz
Journal: Circulation (2020)

Introduction: Creatinine-based estimated glomerular filtration rate (eGFR) is biased in the setting of obesity and other conditions. Alternative kidney filtration markers may be particularly useful in adults with diabetes, but few studies examined the risk of clinical outcomes associated with filtration markers in adults with type 2 diabetes. Objective: We evaluated whether baseline levels and change in eGFR based on creatinine (Cr), cystatin C (Cys), and B 2 -microglobulin (B2M) were associated with the risk of clinical outcomes among individuals with type 2 diabetes. Methods: In the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial, Cr, Cys, and B2M were measured in 7,217 participants at baseline and a random sample of 640 participants at the 1 year visit. We categorized baseline eGFR Cr , eGFR Cys , eGFR B2M , and the average across the 3 eGFR estimates (eGFR avg ) into quarters, and examined associations with major macrovascular and microvascular events together, and separately, and all-cause mortality using Cox regression models, adjusting for established risk factors. We also examined associations with continuous eGFR decline and increase (per 30%). Results: Over a median follow-up of 5 years, 1,313 combined major macrovascular (n=748) and microvascular events (n=637), and 743 deaths occurred. Lower levels of eGFR based on all three filtration markers individually and combined were associated with 1.5 to 2.2 times higher risk of combined major macrovascular and microvascular events, with similar patterns for other outcomes ( Table ). Per 30% decline in eGFR Cys and eGFR avg were associated with a &gt;2-fold higher risk of all clinical outcomes, after additional adjustment of baseline eGFR. Conclusions: In adults with type 2 diabetes, baseline levels of eGFR based on alternative filtration markers and per 30% decline in eGFR Cys and eGFR avg were consistently associated with all clinical outcomes.
Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma
Authors: Jonathan S Cebon, Martin Gore, John F Thompson, Ian D Davis, Grant A McArthur, Euan Walpole, Mark Smithers, Vincenzo Cerundolo, P Rod Dunbar, Duncan MacGregor, Cyril Fisher, Michael Millward, Paul Nathan, Michael P N Findlay, Peter Hersey, T R Jeffry Evans, Christian Hermann Ottensmeier, Jeremy Marsden, Angus G Dalgleish, Pippa G Corrie, Marples Maria, Margaret Brimble, Geoff Williams, Sintia Winkler, Heather M Jackson, Liliana Endo-Munoz, Candani S A Tutuka, Ralph Venhaus, Lloyd J Old, Dennis Haack, Eugene Maraskovsky, Andreas Behren, Weisan Chen
Journal: Journal for ImmunoTherapy of Cancer (2020)

To compare the clinical efficacy of New York Esophageal squamous cell carcinoma-1 (NY-ESO-1) vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in a randomized, double-blind phase II study in participants with fully resected melanoma at high risk of recurrence. Participants with resected stage IIc, IIIb, IIIc and IV melanoma expressing NY-ESO-1 were randomized to treatment with three doses of NY-ESO-1/ISCOMATRIX or ISCOMATRIX adjuvant administered intramuscularly at 4-week intervals, followed by a further dose at 6 months. Primary endpoint was the proportion free of relapse at 18 months in the intention-to-treat (ITT) population and two per-protocol populations. Secondary endpoints included relapse-free survival (RFS) and overall survival (OS), safety and NY-ESO-1 immunity. The ITT population comprised 110 participants, with 56 randomized to NY-ESO-1/ISCOMATRIX and 54 to ISCOMATRIX alone. No significant toxicities were observed. There were no differences between the study arms in relapses at 18 months or for median time to relapse; 139 vs 176 days (p=0.296), or relapse rate, 27 (48.2%) vs 26 (48.1%) (HR 0.913; 95% CI 0.402 to 2.231), respectively. RFS and OS were similar between the study arms. Vaccine recipients developed strong positive antibody responses to NY-ESO-1 (p≤0.0001) and NY-ESO-1-specific CD4+ and CD8+ responses. Biopsies following relapse did not demonstrate differences in NY-ESO-1 expression between the study populations although an exploratory study demonstrated reduced (NY-ESO-1)+/Human Leukocyte Antigen (HLA) class I+ double-positive cells in biopsies from vaccine recipients performed on relapse in 19 participants. The vaccine was well tolerated, however, despite inducing antigen-specific immunity, it did not affect survival endpoints. Immune escape through the downregulation of NY-ESO-1 and/or HLA class I molecules on tumor may have contributed to relapse.
Breast cancer after treatment of Hodgkin disease: Clinical outcome of 38 cases in 27 patients
Authors: M. A. Alm El-Din, K. S. Hughes, S. I. Goldberg, R. A. Raad, A. G. Taghian
Journal: Journal of Clinical Oncology (2007)

11059 Background: Many studies showed that women who are cured of HD have an increased risk of developing BC. Our purpose is to evaluate detection, pathology, management and prognosis of BC occurring after HD. Methods: Thirty-eight cases of BC in 27 survivors of HD were analyzed. All patients received supradiaphragmatic RT and 13 had also chemotherapy for HD. Results: The median age of the patients at diagnosis of HD was 25.5 years. The median interval to develop BC was 15.9 years. The median age at diagnosis of BC was 45.8 years. Ten women (37%) had bilateral disease; one of them had DCIS, 7 years before developing bilateral disease. Cancers were detected by mammography (59.4%), symptom presentation (24.3%), clinical examination (8%), and incidental during elective mastectomy (8%). Using Fisher’s Exact test, DCIS was more frequent (27%), where nodal involvement (29.6%), and ER positivity (81.5%) were paralleled that reported in general population. Thirty tumors (79%) were managed by mastectomy due to prior RT. Two women received RT following mastectomy. Eight tumors treated by lumpectomy, followed by RT in two women; one received whole breast RT, while the other received fractionated partial breast irradiation using 3D-conformal technique (50Gy/25 fractions) and she is doing well 1 1/2 years after RT. Adjuvant systemic therapy, given to 17 patients, was well tolerated. The median follow-up after BC was 61 months. Using Kaplan-Maier procedure, the 6-year actuarial relapse-free survival for node-negative BC after HD was 100%. Node positive patients had a significantly lower RFS of 58.3% ± 19% (P = 0.01). Conclusions: Compared to patients with primary BC, patients developing BC after HD are more likely to be younger, have bilateral disease and have more frequent DCIS. Other pathological features and prognosis are similar to that reported in general population. Patient awareness, breast examination and mammography should be part of the follow-up program for HD survivors. Mastectomy remains the standard of care in most of cases; however, lumpectomy followed by fractionated partial breast irradiation might be a reasonable approach to investigate for women who refuse mastectomy. No significant financial relationships to disclose.
Relation between vascular endothelial growth factor receptor (VEGFR) in tumor sample and response rate in patients with cervical cancer treated with chemo-radiotherapy
Authors: E. Richardet, M. Richardet, M. B. Mascheroni, A. Lingua, P. Gómez Storniolo, P. Celiz, S. Bella, A. Guidi, G. Ferraris, L. Kaen, M. De la Colina
Journal: Journal of Clinical Oncology (2007)

16040 Background: The vascular endothelial growth factor (VEGF) and their receptors play a fundamental role in the regulation of the angiogenesis and linfoangiogenesis. This study examined the relation between levels of expression of the VEGFR with the rate of response in patients (pts) with cervical cancer treated with chemo-radiotherapy-brachytherapy with cisplatinum. Methods: Clinical records of 30 women with their pathology were analyzed. The expression of the VEGFR was evaluated by inmunohistochemestry (IHQ-) by a pathologists committee and It was classified in 4 categories according percentage of tumor cells cytoplasm marked: 0 = 0% / 1=&lt; 25% / 2=&lt;26%-50% and 3 = &gt; 50%. In order to correlate the VEGFR expression with response rate, patients were classified in 2 groups: lower level of expression (VEGFR 0–1), and high level of expression (VEGFR 2–3). In a second analysis we discriminated those with VEGFR expression 3 ant the rest of the group. The evaluation of the tumor response was made by clinical examination and magnetic nuclear resonance (RNM). We used Fisher exact test for statistical analysis Results: Median age: 47 years (r: 27 - 69). Pts with VEGFR 0 =2 (6.66%) pt with 1,2,3 VEGFR =28 (93.33%)(p:&lt;0,001) . Objective respnse rate (OR) in pts with low expression of VEGFR was 90.9%, OR rate for pts with high levels of expression VEGFR was 56.97% (p: 0,52). The OR rate for pts with VEGFR 3 OR was 28.57% and for pats with VEGFR 0,1,2 was 69.56% (p:0,035) Conclusions: We observed that 93.33% of pts expresed VEGFR. OR rate was higher among pts. with lower expression compared with pts. of higher level of expression. These results, although in a small group of patients, stimulate investigation of anti angiogenic therapies in cervical cancer. [Table: see text]